Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease

Eisai

Status and phase

Completed

Phase 3

Conditions

Alzheimer's Type Dementia

Treatments

Drug: E2020

Study type

Interventional

Funder types

Industry

Identifiers

NCT01539031

E2020-J081-343

Details and patient eligibility

About

The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.

Enrollment

351 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Diagnosis: diagnostic evidence of probable Alzheimer's disease (AD) consistent with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) 290.00 or 290.10
Mini Mental State Examination (MMSE) less than or equal to 12 and greater than or equal to1 inclusive, at Screening
SIB less than or equal to 90 and greater than or equal to10 at both Screening and Baseline
No evidence of focal disease to account for dementia on any cranial image (magnetic resonance imaging [MRI] or computed tomography [CT]).
Subject age range: male and female subjects greater than or equal to 50 years of age inclusive
Outpatients (patients in nursing homes are eligible)
The subject must have a caregiver who will provide informed consent separately for his/her own participation in the study, who will have regular contact with the subject.
Stable donepezil dose of 10 mg, taken as a single, daily dose for greater than or equal to 3 months prior to the Screening visit
Subjects who can swallow hole tablets, as tablets should not be broken or crushed
Comorbid medical conditions must be clinically stable prior to Screening unless otherwise specified.
Written informed consent will be obtained from the subject (if possible) or from the subject's legal guardian or other representative (according to Japanese regulations as appropriate) prior to beginning screening activities.

Exclusion Criteria

Subjects with a known history of disorders that affect cognition or the ability to assess cognition but are distinguishable from AD
Subjects with dementia complicated by other organic disease or AD with delirium
Known hypersensitivity to donepezil or piperidine derivatives, or to any of the excipients in the study drug formulation
Patients who are expected to live in a nursing home within 24 weeks after randomization (eligible if temporary)
Use of any prohibited prior or concomitant medications. Memantine will be allowed if taken at prescribed doses that are less than or equal to 20 mg/day, provided that the dose has been stable for at least 6 months prior to Screening.